Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller, CMR Hernandez - Thrombosis Research, 2017 - Elsevier
Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller… - Thrombosis …, 2017 - thrombosisresearch.com
Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller… - Thrombosis …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller, R Hernandez - Thrombosis Research, 2016 - europepmc.org
Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller, CMR Hernandez - Thrombosis Research, 2017 - infona.pl
The standard of care for the treatment of cancer-related venous thromboembolism (VTE) is a
low molecular weight heparin (LMWH) formulation. The recent development of direct oral …
low molecular weight heparin (LMWH) formulation. The recent development of direct oral …
[引用][C] Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller, CMR Hernandez - Thrombosis Research, 2017 - cir.nii.ac.jp
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus
conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A …
conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A …
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous …
JA Ross, MM Miller… - Thrombosis …, 2017 - mdanderson.elsevierpure.com
Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …